Citations 1
Double blind phase III trial of effects of low dose 13-cisretinoic acid on prevention of second primaries in stages I-II head and neck cancer: A trial of the ECOG-ACRIN Cancer Research Group (C0590).
Bhatia, Aarti , Lee, Ju‐Whei , Pinto, Harlan , Jacobs, Charlotte, Arusell, Robert M., Dunphy, Eamonn P., Khandekar, Janardan D., Reiner, Seth, Báez-Díaz, Luis , Celano, Paul , Li, Yi , Pandya, Kishan J., Pinto, Harlan A. , Limburg, Paul J. , Li, Shuli , Burtness, Barbara
Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 1507-1507
